×

Immunomic Therapeutics Explains Proprietary LAMP-vax Platform in Nature Advertorial Supplement

HERSHEY, Pa., and ROCKVILLE, Md., March 3, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has published an article as an advertorial supplement in the March 2015 issue of Nature Biotechnology and Nature Reviews Drug Discovery that outlines the benefits of the company's platform.

The article, penned by ITI CEO, William Hearl, Ph.D., outlines the way the company's LAMP (lysosome-associated membrane protein) DNA vaccine technology helps the immune system process allergens and other antigens, based on its unique approach of boosting the immune system's reaction to the DNA vaccines it delivers.

The article continues to outline the company's varied pipeline, including vaccines for Japanese Red Cedar, for which it is partnering with Astellas in Japan, as well as other programs the company is currently working on, including licensed oncology and immunology applications and a peanut allergy vaccine.

"We believe that the LAMP-vax platform may completely change the way we approach allergies, and has tremendous potential in the delivery of DNA-based therapeutics in general," said Dr. Hearl. "While we are planning peer reviewed publications, we thought it important to begin to inform professionals about LAMP-vax's potential."

The company's article can be accessed via the website for Biopharma Dealmakers: http://www.nature.com/biopharmadealmakers/index.html and the specific article at http://viewer.zmags.com/publication/f1ad96ea

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:

  • ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
    • An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
  • ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
  • Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.

For more information about ITI and LAMP Technology, please visit www.immunomix.com.

CONTACT: Jules Abraham JQA Partners, Inc. jabraham@jqaparnters.com (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc sia@immunomix.com http://www.immunomix.com (717) 327-1822Source:Immunomic Therapeutics, Inc.